Last reviewed · How we verify
Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease
The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.
Details
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 4 |
| Status | ENROLLING_BY_INVITATION |
| Enrolment | 50 |
| Start date | 2023-05-08 |
| Completion | 2026-09 |
Conditions
- Lewy Body Disease
- Dementia
- Parkinsonism
- Mild Cognitive Impairment
- REM Sleep Behavior Disorder
Interventions
- meta-iodobenzylguanidine (MIBG) (123I)
- 123I-MIBG scintigraphy
Primary outcomes
- Correlate myocardial 123I-MIBG scintigraphy findings — 10 years
Number of myocardial 123I-MIBG scintigraphy findings to correlate with clinical pathologic diagnosis
Countries
United States